IFNAR1 and systemic lupus erythematosus: In particular, analysis of data obtained from the trials indicated that anifrolumab suppressed inflammatory proteins associated with disease activity, improved markers of cardiometabolic disease, and reversed SLE-related cytopenias, supporting the broad impact of IFNAR1 blockade [2].